Biocon Ltd

Basis of our Recommendation

Biocon Ltd is poised for accelerated growth, driven by the successful integration of its biosimilars and generics segments, as highlighted by management's recent commentary. The completion of major capital expenditures allows the company to focus on operational leverage and high-margin product launches, particularly in the biosimilars space, which remains a key growth engine. With a robust pipeline and expanded manufacturing capacity, Biocon anticipates a stronger performance in the latter half of FY27, supporting Vista's forecast of accelerating revenue growth beyond historical levels. However, the company faces near-term challenges in its research services segment, which may temper overall performance. The industry context remains favorable, with improving pricing power and a growing demand for Indian CDMOs, although raw material shortages and regulatory complexities pose risks. Over the next 12-24 months, key opportunities include the successful commercialization of new biosimilars and the potential for margin expansion, while watchpoints include the recovery trajectory of the Syngene segment and external market pressures. Overall, Biocon's strategic focus on profitable growth and disciplined capital allocation underpins Vista's outlook for stable margins and fair valuation